Zynerba Analyst Says Stock A Buy Ahead Of Zygel Data Release In 2020
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares ended Monday’s session nearly 15% higher after Canaccord Genuity said the stock’s mid-September sell-off was unjustified. The Analyst Sumant Kulkarni maintained a Buy rating on Zynerba with an $18 price target. The Thesis The Phase 2 data for Zygel released in mid-September was misunderstood …
News story posted on 2019-12-17T01:32:00.0000000Z
